MultiHance 用於肝臟顯影之相關文獻

Vaneckova M, Herman M, Smith MP, Mechl M, Maravilla KR, Weichet J, Spampinato MV, Žižka J, Wippold FJ 2nd, Baima JJ, Babbel R, Bültmann E, Huang RY, Buhk JH, Bonafé A, Colosimo C, Lui S, Kirchin MA, Shen N, Pirovano G, Spinazzi A.

The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)

AJNR Am J Neuroradiol. 2015 Jul 16. [Epub ahead of print]

www.ncbi.nlm.nih.gov/pubmed/26185325

 

Shin KS, AlObaidy M, Ramalho M, Jeon YH, Burke LM, Altun E, Stallings CG, Semelka RC. Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study. Abdom Imaging. 2014 Sep 16. [Epub ahead of print]

www.ncbi.nlm.nih.gov/pubmed/25223524

 

Davenport MS, Khalatbari S, Liu PS, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK. Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging. Radiology. 2014 Jul;272(1):132-42.

www.ncbi.nlm.nih.gov/pubmed/24555636

 

Thomeer MG, Willemssen FE, Biermann KK, El Addouli H, de Man RA, Ijzermans JN, Dwarkasing RS. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents. J Magn Reson Imaging. 2014 May;39(5):1259-64.

www.ncbi.nlm.nih.gov/pubmed/23897798

 

Fontarensky M1, Montoriol PF, Buc E, Poincloux L, Petitcolin V, Da Ines D. Advantages of gadobenate dimeglumine-enhanced MR cholangiography in the diagnosis of post-liver transplant bile leakage. Diagn Interv Imaging. 2013 Apr;94(4):443-52.

www.ncbi.nlm.nih.gov/pubmed/23433543

 

Jeong WK, Kim YK, Song KD, Choi D, Lim HK. The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase. Clin Mol Hepatol. 2013 Dec;19(4):360-6

www.ncbi.nlm.nih.gov/pubmed/24459639

 

Thian YL, Riddell AM, Koh DM. Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging. 2013 Dec 30;13(4):567-79.

www.ncbi.nlm.nih.gov/pubmed/24434892

 

Yeom SK, Byun JH, Kim HJ, Park SH, Kim N, Shin YM, Kim PN. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis. Magn Reson Imaging. 2013 Jul;31(6):911-7.

www.ncbi.nlm.nih.gov/pubmed/23598063

 

Ringe KI, Boll DT, Husarik DB, Bashir MR, Gupta RT, Merkle EM. Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents--comparison of Gd-EOB-DTPA and Gd-BOPTA. BMC Med Imaging. 2013 Mar 18;13:10.

www.ncbi.nlm.nih.gov/pubmed/23506523

 

Fontarensky M, Montoriol PF, Buc E, Poincloux L, Petitcolin V, Da Ines D. Advantages of gadobenate dimeglumine-enhanced MR cholangiography in the diagnosis of post-liver transplant bile leakage. Diagn Interv Imaging. 2013 Apr;94(4):443-52.

www.ncbi.nlm.nih.gov/pubmed/23433543

 

Burke C, Alexander Grant L, Goh V, Griffin N. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging. Semin Ultrasound CT MR. 2013 Feb;34(1):44-53.

www.ncbi.nlm.nih.gov/pubmed/23395317

 

Pradella S, Lucarini S, Colagrande S. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma. AJR Am J Roentgenol. 2012 Nov;199(5):W662. doi: 10.2214/AJR.12.8951.

www.ncbi.nlm.nih.gov/pubmed/23096214

 

Koh DM. Liver-specific contrast agents. Cancer Imaging. 2012 Sep 28;12:363-4.

www.ncbi.nlm.nih.gov/pubmed/23023233

 

Gatto A, De Gaetano AM, Giuga M, Ciresa M, Siciliani L, Miele L, Riccardi L, Pizzolante F, Rapaccini GL, Gasbarrini A, Giuliante F, Vecchio FM, Pompili M, Bonomo L. Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging. Abdom Imaging. 2013 Aug;38(4):736-44.

www.ncbi.nlm.nih.gov/pubmed/22986351

 

Hohmann J, Newerla C, Müller A, Reinicke C, Skrok J, Frericks BB, Albrecht T. Hepatic transit time analysis using contrast enhanced MRI with Gd-BOPTA: A prospective study comparing patients with liver metastases from colorectal cancer and healthy volunteers. J Magn Reson Imaging. 2012 Dec;36(6):1389-94.

www.ncbi.nlm.nih.gov/pubmed/22893441

 

Brismar TB1, Kartalis N, Kylander C, Albiin N. MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine. Eur Radiol. 2012 Mar;22(3):633-41.

www.ncbi.nlm.nih.gov/pubmed/21953376

 

Frydrychowicz A, Lubner MG, Brown JJ, Merkle EM, Nagle SK, Rofsky NM, Reeder SB. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging. 2012 Mar;35(3):492-511

www.ncbi.nlm.nih.gov/pubmed/22334493

 

Fu GL, Du Y, Zee CS, Yang HF, Li Y, Duan RG, Zeng NL, Xiao DM. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions. J Comput Assist Tomogr. 2012 Jan-Feb;36(1):14-9.

www.ncbi.nlm.nih.gov/pubmed/22261765

 

Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics. 2011 Oct;31(6):1547-68.

www.ncbi.nlm.nih.gov/pubmed/21997981

 

Dahlqvist Leinhard O, Dahlström N, Kihlberg J, Sandström P, Brismar TB, Smedby O, Lundberg P. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol. 2012 Mar;22(3):642-53.

www.ncbi.nlm.nih.gov/pubmed/21984449

 

Becker-Weidman DJ, Kalb B, Sharma P, Kitajima HD, Lurie CR, Chen Z, Spivey JR, Knechtle SJ, Hanish SI, Adsay NV, Farris AB 3rd, Martin DR. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements. Radiology. 2011 Dec;261(3):824-33.

www.ncbi.nlm.nih.gov/pubmed/21969663

 

Kim TK1, Lee KH, Jang HJ, Haider MA, Jacks LM, Menezes RJ, Park SH, Yazdi L, Sherman M, Khalili K. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology. 2011 Jun;259(3):730-8.

www.ncbi.nlm.nih.gov/pubmed/21364083

 

Frydrychowicz A, Nagle SK, D'Souza SL, Vigen KK, Reeder SB. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging. 2011 Sep;34(3):585-94

www.ncbi.nlm.nih.gov/pubmed/21751288

 

Jeong WK, Byun JH, Lee SS, Won HJ, Kim KW, Shin YM, Kim PN, Lee MG. Gadobenate dimeglumine-enhanced liver MR imaging in cirrhotic patients: quantitative and qualitative comparison of 1-hour and 3-hour delayed images. J Magn Reson Imaging. 2011 Apr;33(4):889-97.

www.ncbi.nlm.nih.gov/pubmed/21448954

 

Fidler J, Hough D. Hepatocyte-specific magnetic resonance imaging contrast agents. Hepatology. 2011 Feb;53(2):678-82.

www.ncbi.nlm.nih.gov/pubmed/21274888

 

Turkbey B, Akpinar E, Balli O, Tirnaksiz B, Akata D, Akhan O, Karcaaltincaba M. Clinical applications of gadobenate dimeglumine-enhanced magnetic resonance cholangiography: an expanded pictorial review. Jpn J Radiol. 2011 Jan;29(1):3-10.

www.ncbi.nlm.nih.gov/pubmed/21264655

 

Wiwanitkit V. MRI findings of hepatocellular carcinoma. Magn Reson Imaging. 2011 Feb;29(2):303.

www.ncbi.nlm.nih.gov/pubmed/21129874

 

Seale MK1, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009 Oct;29(6):1725-48.

www.ncbi.nlm.nih.gov/pubmed/19959518

 

Marin D1, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, Masciangelo R, Catalano C, Passariello R. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009 Apr;251(1):85-95.

www.ncbi.nlm.nih.gov/pubmed/19332848

 

Kuwatsuru R1, Kadoya M, Ohtomo K, Tanimoto A, Hirohashi S, Murakami T, Tanaka Y, Yoshikawa K, Katayama H. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol. 2001 Nov;36(11):632-41.

www.ncbi.nlm.nih.gov/pubmed/11606840

 

Petersein J1, Spinazzi A, Giovagnoni A, Soyer P, Terrier F, Lencioni R, Bartolozzi C, Grazioli L, Chiesa A, Manfredi R, Marano P, Van Persijn Van Meerten EL, Bloem JL, Petre C, Marchal G, Greco A, McNamara MT, Heuck A, Reiser M, Laniado M, Claussen C, Daldrup HE, Rummeny E, Kirchin MA, Pirovano G, Hamm B. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. Radiology. 2000 Jun;215(3):727-36.

www.ncbi.nlm.nih.gov/pubmed/10831691

 

Kuwatsuru R1, Kadoya M, Ohtomo K, Tanimoto A, Hirohashi S, Murakami T, Tanaka Y, Yoshikawa K, Katayama H. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S65-74.

www.ncbi.nlm.nih.gov/pubmed/10608400

 

Manfredi R1, Maresca G, Baron RL, Cotroneo AR, De Gaetano AM, De Franco A, Pirovano G, Spinazzi A, Marano P. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging. 1999 May;9(5):704-10.

www.ncbi.nlm.nih.gov/pubmed/10331767

 

 

聯絡我們

普樂可醫藥股份有限公司 地址 : 台北市民生東路一段58號11樓 電話 : (02) 2521-0566
傳真 : (02) 2571-0157
p5418173@ms17.hinet.net